Abstract: The present invention provides an oral care composition which includes one or more nonpolar structuring agents, one or more emulsifiers, one or more mucoadhesive polymers, and one or more active ingredients effective for providing oral pain relief. The oral care composition can be a solid or semi-solid composition up to a temperature of at least 40° C. Methods of providing such an oral care composition are also provided herein.
Type:
Grant
Filed:
May 25, 2018
Date of Patent:
December 26, 2023
Assignee:
Church & Dwight Co., Inc.
Inventors:
Jennifer Benson, Elena Petrovicova, William D. Platt
Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
August 11, 2023
Date of Patent:
December 26, 2023
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
Type:
Grant
Filed:
June 2, 2021
Date of Patent:
December 19, 2023
Assignees:
MESHABERASE, LLC, The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors:
Benjamin Rubin, Mark Gilbert, Jinkyu Jung
Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
August 11, 2023
Date of Patent:
December 19, 2023
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: A flurbiprofen axetil emulsion for injection can be prepared by specific stepwise addition of an oil phase to a water phase with shear mixing under the protection of nitrogen gas to obtain an emulsion. The oil phase includes flurbiprofen axetil, an oil phase solvent, an emulsifier, and a stabilizer, and the water phase includes water for injection and/or an osmotic pressure regulator. In the presence of a stabilizer in the oil phase, the emulsion can improve the emulsification effect by using the stepwise emulsifying technique for the oil phase, so that the obtained flurbiprofen axetil emulsion for injection has more uniform particle size, higher drug entrapment efficiency, and better targeting of the drug to the wounded tissue.
Type:
Grant
Filed:
January 21, 2019
Date of Patent:
December 12, 2023
Assignee:
Grand life science (wuhan) co., LTD
Inventors:
Ling Huang, Xiaohua Zhang, Jinchun Song, Lei Yin
Abstract: A sterile aqueous formulation of a carbonic anhydrase inhibitor such as brinzolamide in combination with polymers like Soluplus® and a surfactant like polysorbate 80, as well as methods of preparation thereof, is disclosed. The formulation relates to the highly solubilized or an amorphous form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.
Abstract: Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9. Further provided herein are compositions and methods of treating conditions related to coronary disease.
Type:
Grant
Filed:
November 23, 2021
Date of Patent:
October 31, 2023
Assignee:
Verve Therapeutics, Inc.
Inventors:
Kallanthottathil G. Rajeev, Souvik Biswas, Padma Malyala, Lisa N. Kasiewicz, Alexandra Chadwick, Caroline Reiss
Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
March 6, 2023
Date of Patent:
October 24, 2023
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
Type:
Grant
Filed:
September 9, 2021
Date of Patent:
October 17, 2023
Assignee:
TAPESTRY PHARMACEUTICALS, INC.
Inventors:
James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
Abstract: Clear bioavailable liquid softgel fill compositions comprising a) at least one analgesic and one or more of decongestants, expectorants, antitussives and/or antihistamines; b) a matrix comprising a pharmaceutically acceptable poly(alkylene glycol) and a pharmaceutically acceptable alkylene glycol; c) a solubilizing agent comprising a pharmaceutically acceptable polymeric solubilizing agent and water are disclosed. Also disclosed are methods for the preparation of such clear fill compositions, and softgel capsules containing the clear bioavailable liquid fill composition.
Type:
Grant
Filed:
March 11, 2022
Date of Patent:
September 26, 2023
Assignee:
PuraCap Pharmaceutical LLC
Inventors:
Dahai Guo, Minh Tran, Zhang Julia Zhang
Abstract: A particulate form of dithiocarbamate-metal complex and at least one blood protein. The particulate form is obtained by a process having a sequential or simultaneous addition of individual components, resulting in their self-assembling. The aqueous dispersion of the particulate form is suitable for parenteral, oral and topical administration and for therapy and visualization of cancer.
Type:
Grant
Filed:
September 26, 2018
Date of Patent:
September 26, 2023
Assignee:
PALACKY UNIVERSITY OLOMOUC
Inventors:
Zdenek Skrott, Martin Mistrik, Marian Hajduch, Petr Dzubak, Jiri Bartek, Radek Zboril
Abstract: The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.
Type:
Grant
Filed:
April 15, 2021
Date of Patent:
September 19, 2023
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
September 19, 2023
Assignee:
Temple University-Of The Commonwealth System of Higher Education
Inventors:
Ira C. Spector, Mark A. Feitelson, Alla Arzumanyan
Abstract: An article including an antimicrobial core material and a shielding material encasing the core material such that the core material is not exposed to the ambient surroundings. The shielding material includes an exterior surface, and the core material includes an antimicrobial material configured to eliminate the pathogens on the exterior surface without contacting the pathogens. Furthermore, the shielding material includes a varying density of antimicrobial particles.
Abstract: Embodiments of the present invention pertain to glass compositions, glasses and articles. The articles include an aluminosilicate glass, which may include P2O5 and K2O.
Type:
Grant
Filed:
April 18, 2022
Date of Patent:
September 12, 2023
Assignee:
Corning Incorporated
Inventors:
Dana Craig Bookbinder, Gary Stephen Calabrese, Timothy Michael Gross, Dayue Jiang, Jianguo Wang
Abstract: Provided is a disinfectant against Legionella, including an iron salt as an active ingredient. Examples of the iron salt include ferrous salts such as iron (II) sulfate (ferrous sulfate), and ferric salts such as ammonium iron (III) sulfate (ferric ammonium sulfate). Provided is a method for treating water, including bringing target water into a state in which the target water contains an iron salt or an iron ion, thereby suppressing or inhibiting proliferation of Legionella existing in the target water. The present invention can sterilize and disinfect Legionella existing in, for example, bathtub water and air-conditioning cooling tower water, with high safety and sense of security in a simple and easy manner.
Abstract: A hygiene product, a hygiene product pod, and a method of using the hygiene product pod, the hygiene product pod including a water soluble envelope and the hygiene product sealed in the envelope. The hygiene product includes a carrier comprising butylene glycol in an amount ranging from about 40 wt % to about 70 wt %, based on the total weigh of hygiene product, and an active agent including at least one surfactant.
Type:
Grant
Filed:
October 2, 2018
Date of Patent:
September 5, 2023
Assignee:
Nohbo, Inc.
Inventors:
Benjamin Gabriel Stern, Robert Hutton Ray, James J. Ramirez, Matthew Gernstein
Abstract: A method is provided for treating pathogens with a lipid-based carrier and organic acids. More specifically the lipid carrier may have a pKa of 2.5-4.0 and/or may be acid oil, such as Acidulated Vegetable Oil. Furthermore, compositions consistent with the method are provided wherein the lipid-based carrier increases antipathogenic action of the organic acid. For example, the carrier may have a pKa that increases the antimicrobial action of the organic acid and/or an additional essential oil. The carrier may be acid oil, such as Acidulated Vegetable Oil derived from soapstocks and/or gums, but is not limited to same. The organic acid may include, but is not limited to, formic acid, acetic acid, propionic acid, butyric acid, and combinations thereof.
Type:
Grant
Filed:
September 13, 2018
Date of Patent:
August 22, 2023
Assignee:
RRIP, LLC
Inventors:
Mohan Prasad A. Dasari, Abdullah A. Mahfuz
Abstract: The invention relates to a solid pharmaceutical tablet for oral delivery, the tablet comprising calcium carbonate in an amount of more than 30% by weight of the tablet and organic water-insoluble components in an amount of more than 20% by weight of the tablet, wherein the tablet is designed to be masticated into a coherent residual containing the organic water-insoluble components, and wherein the tablet is adapted to release more than 80% of the calcium carbonate within 5 minutes of mastication.
Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.
Type:
Grant
Filed:
September 16, 2021
Date of Patent:
August 8, 2023
Assignee:
Tolmar, Inc.
Inventors:
Eric Dadey, John Middleton, Richard L. Norton